APGE director files Form 144 for 6,000 shares

APGE reported a Form 144 notifying the sale of 6,000 restricted shares of Common Stock by Jane Henderson.

Rhea-AI Filing Summary

APGE reported a Form 144 notifying the sale of 6,000 restricted shares of Common Stock by Jane Henderson. The filing lists four 10b5-1 sales across 01/02/2026, 01/06/2026, 02/02/2026, and 03/02/2026 with per-trade share counts of 6,000, 2,000, 2,000 and 2,000 respectively and reported proceeds per trade in the filing.

Insights

Securities Compliance Counsel

Routine Form 144 reports structured 10b5-1 sales of restricted shares.

The filing documents the sale of restricted Common Stock under a disclosed 10b5-1 plan by Jane Henderson; the listed securities to be sold total 6,000 shares tied to a Restricted Stock Award dated 02/01/2023.

Timing and proceeds are shown per trade; cash-flow treatment is the selling holder's receipts. This is a standard Section 16 disposition filing and does not by itself imply regulatory noncompliance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did APGE's Form 144 disclose about the sales?

The filing discloses a Form 144 by Jane Henderson reporting the sale of 6,000 restricted shares. It lists four 10b5-1 transactions dated 01/02/2026, 01/06/2026, 02/02/2026, and 03/02/2026 with proceeds reported per trade.

Who conducted the sales reported in the APGE Form 144?

The sales were reported by Jane Henderson and executed under a 10b5-1 plan. The filing attributes the securities to a Restricted Stock Award dated 02/01/2023 and shows the sales as dispositions of those restricted shares.

How many shares were listed as "securities to be sold" for APGE?

The filing lists 6,000 shares of Common Stock as the securities to be sold, associated with a Restricted Stock Award dated 02/01/2023. The filing pairs that listed amount with the per-trade transactions shown in the sale history.

Do the Form 144 entries show how proceeds were handled?

The filing reports proceeds for each 10b5-1 sale as individual trade amounts next to the dates and share counts. It does not state company receipt of proceeds; proceeds are reported as part of the selling-holder transaction lines in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 04:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001422304
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	APOGEE THERAPEUTICS INC
SEC File Number	001-41740
Address of Issuer	221 Crescent St., Building 17 Waltham MASSACHUSETTS 02453
Phone	6503945230
Name of Person for Whose Account the Securities are To Be Sold	JANE HENDERSON
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6000	438000.00	55998605	03/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2023	Restricted Stock Award	Issuer			6000	02/01/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JANE HENDERSON 221 Crescent St., Building 17 Waltham MA 02453	Common	03/02/2026	2000	140430.40
10b5-1 Sales for JANE HENDERSON 221 Crescent St., Building 17 Waltham MA 02453	Common	02/02/2026	2000	131622.00
10b5-1 Sales for JANE HENDERSON 221 Crescent St., Building 17 Waltham MA 02453	Common	01/06/2026	2000	160000.00
10b5-1 Sales for JANE HENDERSON 221 Crescent St., Building 17 Waltham MA 02453	Common	01/02/2026	6000	449170.00

144: Remarks and Signature

Remarks
Date of Notice	03/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/02/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jane Henderson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)